Navigation Links
Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society of Clinical Oncology (ASCO) 2007 Annual Meeting

CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. and Bristol-Myers Squibb Company today presented results from multiple clinical studies of ipilimumab (MDX-010), an investigational immunotherapy, for patients with advanced melanoma. The results demonstrated an anti-tumor response in some patients with advanced melanoma either as a monotherapy or in combination with other therapies. The results of the monotherapy study showed that 19% of patients (17/88) with advanced melanoma treated with ipilimumab experienced control of their disease, including tumor shrinkage and stabilization. The second presentation showed that complete or partial response was achieved in 13% of patients (46/356) with advanced melanoma when treated with ipilimumab alone or in combination with traditional chemotherapy (i.e., dacarbazine), interleukin-2, or a gp100 peptide vaccine. The results of this analysis also indicated that treatment with ipilimumab may take 12 weeks or longer to induce a response. These findings were presented at the American Society of Clinical Oncology's 2007 Annual Meeting in Chicago.

"In recent years, there have been limited advancements in the treatment of melanoma, particularly in the later stages of the disease," said Rachel Humphrey, MD, Vice President of Development at Bristol-Myers Squibb. "These studies represent an important advance in our understanding of how ipilimumab may work as a potential anti-cancer therapy for patients with this devastating disease."

(Abstract #8523) Results from a Phase II dose-escalation trial presented by Jeffrey S. Weber, MD, PhD, who was Chief of Oncology at the Keck School of Medicine at the University of Southern California at the time of the study, suggested that the anti-tumor response evolves over time in certain patients treated with ipil
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
2. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
3. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Study Demonstrated Rozerem (ramelteon) Does Not Affect Middle-of-the-Night Balance in Older Adults with Insomnia
6. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
7. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
9. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
10. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
11. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
Post Your Comments:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... 27, 2015 Biosimilars are not generics ... U.S. Food and Drug Administration (FDA) for recognizing ... its draft guidance issued today. The FDA,s draft ... distinguishable names, calling for biological products to bear ... This proposal reflects the agency,s thinking that "there ...
(Date:8/27/2015)... August 27, 2015 According to a new ... Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage ... 2020", published by MarketsandMarkets, the Medical Lifting Sling Market is poised ... in 2015, at a CAGR of 11.4 % from 2015 to ... ma rket data T ables and 65 ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... , , ... 10, 2009 Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, ... clinical trial in patients chronically infected with the hepatitis C virus (HCV). ... the antiviral effect of clemizole monotherapy in the absence of interferon. ...
... LOS ANGELES, Aug. 7 A new drug delivery system that ... to the outer surface (episclera) of the eyeball may offer a ... and vitreous diseases, according to a new report by A. Linn ... at Children,s Hospital Los Angeles. Dr. Murphree is also Professor of ...
Cached Medicine Technology:Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 2Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial 3Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases 2Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases 3Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases 4
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time ... part with their subsidiary USPI Tenet Health. , The American Heart Association hosts their ... and stroke. They believe that together, a difference can be made. Walkers can participate ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and ... to its cadre of widespread support—an official letter of support and gratitude from the ... community and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... ... 28, 2015 , ... Drugs and alcohol abuse by employees ... new approach on solutions in his new book ":Unraveling The Psychological Mystery of ... together for meaningful group meetings. "This would educate the employees on not ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International announced that ... counseling, day treatment and intensive family based services. , By pursuing and achieving ... its pursuit of excellence. As a nonprofit charity for more than 50 years, ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... , SHENZHEN, China, July 9 ... ), a leading developer, manufacturer and,marketer of medical devices ... for the second quarter ended June 30, 2009 after ... will hold an earnings,conference call at 8:00 AM on ...
... Legalized marriage for same-sex couples continues to be a ... California and New Hampshire ... legal recognition. Domestic partners in all states need to get smart ... covered. The National Association of Insurance Commissioners (NAIC) provides these tips ...
... TeamPraxis, Hawaii,s premier physician management service organization (MSO) ... 1,000 Hawaii physicians, capped off its inaugural year of ... market with seven new large client signings, bringing the ... , , These sales completed a very ...
... GXDX ), a provider of personalized diagnostic services, announced ... second quarter of 2009 after closing of the NASDAQ Global Market ... call hosted by President and CEO, Dr. Tina S. Nova, and ... day at 2:00pm PDT (5:00pm EDT) and will be webcast live ...
... (NYSE: CSV ) today announced plans to release 2009 ... closes. In conjunction with the release, Carriage Services has scheduled ... for Friday, July 31, 2009 at 10:30 a.m. eastern time. ... Second Quarter 2009 Earnings Conference Call, When: ...
... 9 Velos, Inc., the trusted leader in clinical ... ever-advancing mission to meet the needs of customers. "Velos ... is now being rolled out more broadly for the ... economies and benefits that support individual studies and departments ...
Cached Medicine News:Health News:Mindray to Report Second Quarter 2009 Financial Results on August 10, 2009 2Health News:Health Insurance Options for Domestic Partnerships 2Health News:Health Insurance Options for Domestic Partnerships 3Health News:TeamPraxis Finishes Strong First Year of National Sales 2Health News:TeamPraxis Finishes Strong First Year of National Sales 3Health News:TeamPraxis Finishes Strong First Year of National Sales 4Health News:TeamPraxis Finishes Strong First Year of National Sales 5Health News:Genoptix, Inc. to Announce Second Quarter 2009 Financial Results 2Health News:Carriage Services Announces Second Quarter Earnings Release and Conference Call Schedule 2Health News:Velos, Inc. Launches 'Velos On-Demand' for Velos eResearch, Bringing Dynamically Scalable Economy to Customers 2Health News:Velos, Inc. Launches 'Velos On-Demand' for Velos eResearch, Bringing Dynamically Scalable Economy to Customers 3
... name in gloves, Polymed has become even better. ... advantages of regular Polymed with the exciting addition ... source of antioxidants, which are vital to healthy ... and powder-free to reduce the potential for latex ...
... Clear View Drapes allow practitioners to ... leg during intraoperative adjustments. Makes it ... access legholder adjustment handles for safe ... even when controls are adjusted through ...
... range of procedure-specific designs for all surgical ... the world. Surgical needs such as strength, ... using different materials to provide performance where ... in a wide array of formats, including ...
CYSTOSCOPY "T". DRAPE...
Medicine Products: